The Role of Steroids Following Selective Laser Trabeculoplasty

This study has been completed.
Information provided by:
West Virginia University Identifier:
First received: November 29, 2006
Last updated: March 28, 2007
Last verified: March 2007
To evaluate whether or not using topical steroids after selective laser trabeculoplasty affects intraocular pressure outcomes.

Condition Intervention
Drug: prednisolone acetate 1%

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: The Role of Topical Prednisolone Acetate Following Selective Laser Trabeculoplasty

Resource links provided by NLM:

Further study details as provided by West Virginia University:

Primary Outcome Measures:
  • Intraocular pressure reduction

Secondary Outcome Measures:
  • Anterior chamber inflammation

Estimated Enrollment: 25
Study Start Date: September 2005
Study Completion Date: June 2006
Detailed Description:
Subjects undergoing bilateral SLT will be randomly assigned to use prednisolone acetate 1% in one eye four times daily with no treatment in the fellow eye, for one week following SLT. Examinations will occur at baseline, and one week, one month and three months after SLT. IOP and anterior chamber inflammation will be noted at each visit.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • glaucoma or ocular hypertension
  • need for bilateral SLT

Exclusion Criteria:

  • eye disease precluding accurate IOP measurement
  • contraindication to topical prednisolone acetate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00406042

United States, West Virginia
West Virginia University Eye Institute
Morgantown, West Virginia, United States, 26505
Sponsors and Collaborators
West Virginia University
Principal Investigator: Tony Realini, MD West Virginia University Eye Institute
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00406042     History of Changes
Other Study ID Numbers: 16678 
Study First Received: November 29, 2006
Last Updated: March 28, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by West Virginia University:

Additional relevant MeSH terms:
Methylprednisolone Hemisuccinate
Methylprednisolone acetate
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Protective Agents processed this record on May 25, 2016